\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesIn two weeks' time, DIANA will share it's second call for innovative technology companies working on solutions that could change the world.
Last year, there were answering more than 1300 innovators with ground-breaking deep technologies across three dual-use Challenges. 44 companies joined the pilot cohort, accelerating their businesses while increasing their networks across the Alliance. Check out what a few of these innovators had to say about DIANA in the video (https://lnkd.in/gdWM-w-3): Water Linked VanWyn Inc. IONATE Astrolight GaltTec REVOBEAM
More information:
With the countdown begun, DIANA hopes you consider joining them to tackle some of the world's most complex and pressing technological challenges. Together, we can help create a more peaceful and resilient global future!
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has published a new round of calls under the Digital Europe programme. The submission period for the following call topics will open on 21 April 2026: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
